Objective: Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this systematic review was to systematically review the efficacy and safety of heparin thromboprophylaxis in medical-surgical patients in the ICU. Data Sources: We searched EMBASE, MEDLINE, the Cochrane Controlled Trials Register, Clinicaltrials.gov, and personal files through May 2012. Study Selection: Randomized trials in adult medical-surgical ICU patients comparing any heparin (unfractionated heparin or lowmolecular-weight heparin) with each other or no anticoagulant prophylaxis, evaluating deep vein thrombosis, pulmonary embolism, major bleeding, or mortality. Data Extraction: Independently, in duplicate, we abstracted trial characteristics, outcomes, and risk of bias. Data Synthesis: Seven trials involved 7,226 patients. Any heparin thromboprophylaxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41, 0.63]; p < 0.0001; I 2 = 77%) and pulmonary embolism (risk ratio, 0.52 [95% CI, 0.28, 0.97]; p = 0.04; I 2 = 0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25]; p = 0.43). Major bleeding (risk ratio, 0.82 [95% CI, 0.56, 1.21]; p = 0.32; I 2 = 50%) and mortality (risk ratio, 0.89 [95% CI, 0.78, 1.02]; p = 0.09; I 2 = 0%) rates were similar. Compared with unfractionated heparin, low-molecular-weight heparin reduced rates of pulmonary embolism (risk ratio, 0.62 [95% CI, 0.39, 1.00]; p = 0.05; I 2 = 53%) and symptomatic pulmonary embolism (risk ratio, 0.58 [95% CI, 0.34, 0.97]; p = 0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08]; p = 0.26; I 2 = 0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25]; p = 0.44; I 2 = 0%), major bleeding (risk ratio, 0.97 [95% CI, 0.75, 1.26]; p = 0.83; I 2 = 0%), or mortality (risk ratio, 0.93 [95% CI, 0.82, 1.04]; p = 0.20; I 2 = 31%). Conclusions: Trial evidence to date suggests that any type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgical critically ill patients, and low-molecular-weight heparin compared with bid unfractionated heparin decreases pulmonary embolism and symptomatic pulmonary embolism. Major bleeding and mortality rates do not appear to be significantly influenced by heparin thromboprophylaxis in the ICU setting. Trial methodology, indirectness, and the heterogeneity and imprecision of some results temper inferences from this literature.
severe illness, sedating medications, and invasive procedures (4, 5) . However, critically ill patients are also at high risk of bleeding (6) . Therefore, anticoagulant thromboprophylaxis in the ICU must consider trade-offs between dynamic thrombotic and bleeding risks.
Early research suggested that symptomatic or asymptomatic DVT without thromboprophylaxis (7) develops in 13-31% of medical-surgical critically ill patients. In observational studies of ICU patients receiving LMWH, the frequency of VTE at any site (whether detected by surveillance or clinically suspected then objectively confirmed) ranged from 5.1% to 15.5% and bleeding complications from 7.2% to 23.1% (8) . Low-dose UFH compared with placebo was effective in reducing asymptomatic DVT by approximately 50%, based on the first randomized clinical trial (RCT) in this population (9) . A review summarizing three observational studies and one RCT concluded that thromboprophylaxis with UFH or LMWH was likely more effective than no prophylaxis VTE (10) .
Over a decade ago, the ICU was referred to as the last frontier for prophylaxis (11) . Subsequently, the LMWH nadroparin was found to have a 45% relative risk reduction for asymptomatic DVT compared with placebo in a trial of mechanically ventilated chronic obstructive pulmonary disease patients (12) . Although other RCTs were published since then (13) (14) (15) , no synthesis of this evidence exists.
Trials of mechanical thromboprophylaxis with and without pharmacologic prophylaxis have been summarized in other systematic reviews in surgical and trauma patients (16, 17) . However, in medical-surgical critically ill patients, there are no published trials comparing mechanical prophylaxis with another method of mechanical prophylaxis, or with pharmacologic prophylaxis, or in addition to pharmacologic prophylaxis.
The objective of this systematic review was to synthesize the RCTs comparing heparin (UFH or LMWH) thromboprophylaxis strategies with each other or no prophylaxis in medical-surgical ICU patients on any of the following outcomes: DVT, PE, major bleeding, heparin-induced thrombocytopenia (HIT), and mortality.
MATERIALS AND METHODS

Data Sources and Searches
We searched three databases (EMBASE, MEDLINE, and the Cochrane Controlled Trials Register and Database of Systematic Reviews) from 1980 until May 2012, independently and in triplicate (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/A665). We searched clinicaltrials.gov, our personal trials, and reference lists of eligible studies and review articles for additional trials.
Study Selection
To be included, four criteria were necessary: 1) design: RCT; 2) population: medical or surgical critically ill patients older than or equal to 18 years old; 3) intervention: any heparin thromboprophylaxis compared with any other strategy or no prophylaxis; and 4) outcomes: any VTE outcomes (e.g., DVT or PE, whether symptomatic or asymptomatic), major bleeding, HIT, or mortality. We defined a critically ill patient as a patient cared for in an ICU setting. Trials were excluded if they were pseudorandomized or if they enrolled pediatric, trauma, neurosurgery, or cardiac surgery populations. We had no language restrictions.
In duplicate and independently, two of three reviewers selected articles by examining titles, followed by abstracts and the full text if a potentially relevant trial was identified. Agreement was assessed using kappa.
Data Extraction and Quality Assessment
In duplicate and independently, two of three reviewers abstracted data on the design, population, intervention, comparison, and clinical outcomes. The outcomes of interest were DVT, symptomatic DVT, PE, symptomatic PE, major bleeding, HIT, ICU, and hospital mortality. Definitions of major bleeding were based on the original trial definitions. If the mortality time frame was not specified as either ICU or hospital, we analyzed it as ICU mortality. We wrote to authors to clarify or to obtain missing data.
In duplicate and independently, two of three reviewers assessed the risk of bias of individual trials using the Cochrane risk of bias tool. For each included trial, the risk of bias was reported as "low risk," "unclear risk," or "high risk" in the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias (18) . For each of the outcomes, we independently rated the overall quality of evidence (confidence in effect estimates) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach in which randomized trials begin as high-quality evidence, but it may be rated down by one or more of five categories of limitations: risk of bias, inconsistency, indirectness, imprecision, and publication bias (19) . Disagreement was resolved by discussion and consensus.
Data Synthesis and Analysis
We combined data from all trials to estimate the pooled risk ratio (RR) and associated 95% CIs for all outcomes. If data were available from only one trial, we provide RRs for that trial. For comparisons of any heparin versus control, patients in the heparin group received either UFH or LMWH and patients in the control group received placebo. For comparisons of UFH versus LMWH, the control group was UFH. We also compared UFH versus control and LMWH versus control. Pooled RRs were calculated using the Mantel-Haenszel estimator. Statistical heterogeneity was assessed by the I 2 statistic. This statistic is defined as the proportion of heterogeneity not attributable to chance or random error (i.e., real heterogeneity due to differences in study populations and interventions). Conventionally, I² values greater than 50% suggest substantial heterogeneity (20) . All analyses were conducted in RevMan 5.1. A priori, we hypothesized that most trials would be similar in design, and as our goal was populationspecific estimates, we used a fixed-effects model (21 We had two a priori sensitivity analyses. We examined the effect of excluding studies published only in abstract form as a possible cause of observed heterogeneity. To examine whether using a different relative effect measure would affect our conclusions, we repeated the analysis using odds ratio instead of the RR used in main analysis.
The number of patients needed to prophylax with any type of heparin to prevent one asymptomatic DVT was estimated based on a 10% control rate and 4% PE rate. The DVT rate was obtained from reviews of prospective studies, which found DVT rates of 13-31% among patients receiving no prophylaxis (7) ; we therefore made a conservative DVT estimate of 10%. We estimated a 4% PE rate based on the same ratio of DVT: PE as for the LMWH versus UFH comparison is discussed below. The number of patients needed to prophylax with LMWH versus UFH to prevent one asymptomatic DVT was based on a control rate for DVT of 5% and for PE of 2%, as observed in a large trial evaluating LMWH versus UFH in this population (15) .
RESULTS
Trial Identification
Of 2,472 citations, 41 full-text articles were assessed for eligibility and 34 were excluded (Appendix Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/A665). Overall, five fully published RCTs (9, (12) (13) (14) (15) and two RCTs published in abstract form (22, 23) were included in this systematic review. One included trial was a substudy comparing UFH, LMWH, and placebo for VTE prevention during drotrecogin infusion in patients with sepsis (14) ; the primary trial had evaluated drotrecogin alfa (24) . We abstracted bleeding, HIT, and mortality data from the original report (24) . One trial was reported in two abstracts (22, 25) ; we used the abstract with the most comprehensive results for data abstraction (22) . Agreement on article inclusion was excellent (kappa 1.0).
Trial Characteristics
In Table 1 , we describe characteristics of the seven included trials. Medical and surgical ICU patients were enrolled in three trials (9, 14, 15) , two trials enrolled medical ICU patients (22, 23) , one trial enrolled medical ICU patients with chronic obstructive pulmonary disease (12) , and one trial enrolled surgical ICU patients (13) . Two trials compared UFH with placebo (9, 22) , one trial compared LMWH with placebo (12), three trials compared LMWH with UFH (13, 15, 23) and one trial randomized patients to UFH, LMWH, or placebo in a 1:1:2 ratio (14) . We used this three-arm trial to inform results of all possible two-way comparisons and pooled the results of the UFH and LMWH arms to estimate the effect of any type of heparin thromboprophylaxis compared with none.
Risk of Bias
We did not generate a funnel plot to evaluate possible publication bias because there were only one to four trials contributing to each of the relevant comparisons and outcomes in this review; the Cochrane Collaboration recommends a minimum of 10 or more trials for a valid assessment (26) .
In Table 2 , we report methodologic details of each trial and risk of bias.
Pooled Outcomes
Any Heparin (UFH or LMWH) Versus Placebo
Deep vein thrombosis. Four trials including 3,014 patients (9, 12, 14, 22) reported DVT. The use of UFH or LMWH was associated with a lower risk of DVT when compared with placebo (RR, 0.51 [95% CI, 0.41, 0.63]; p < 0.0001; I 2 = 77%), which translates to a number needed to prophylax to prevent one DVT of 20, using an assumed control risk of 10%. Three trials (9, 14, 22) compared UFH with placebo (RR, 0.48 [95% CI, 0.38, 0.61]; p < 0.0001; I 2 = 82%), and two trials (12, 14) compared LMWH with placebo (RR, 0.72 [95% CI, 0.49, 1.04]; p = 0.08; I 2 = 8%). Only one trial with 1,935 patients reported symptomatic DVT as an outcome, with no difference between groups (RR, 0.86 [95% CI, 0.59, 1.25]; p = 0.43) ( Fig. 1) .
Pulmonary embolism. Three trials including 2,895 patients (12, 14, 22) reported PE. Administration of UFH or LMWH was associated with a lower risk of PE when compared with placebo (RR, 0.52 [95% CI, 0.28, 0.97]; p = 0.04; I 2 = 0%). This translates to number needed to prophylax to prevent one PE of 52, using an assumed control risk of 4%. Two trials with 960 patients (12, 22) compared UFH with placebo; risk of PE was lower in the UFH group (RR, 0.52 [95% CI, 0.28, 0.97]; p = 0.04); and one trial compared LMWH with placebo (14) and showed no difference (RR, 1.00 [95% CI, 0.30, 3.31]; p = 1.0).
Major bleeding. Two trials including 2,156 patients (12, 24) reported major bleeding. There was no difference between heparin prophylaxis and placebo in the risk of major bleeding (RR, 0.82 [95% CI, 0.56, 1.21]; p = 0.32; I 2 = 50%).
Heparin-induced thrombocytopenia. Only one trial including 1,935 patients reported HIT diagnosed by an enzyme-linked immunosorbent assay (14) , with no difference between patients receiving heparin (1.2%) and placebo (1.1%) (RR, 1.07 [95% CI, 0.48, 2.42]; p = 0.87).
ICU mortality. Two trials including 2,148 patients (12, 24) reported mortality. The risk of death was similar in the heparin and placebo groups (RR, 0.89 [95% CI, 0.78, 1.02]; p = 0.09; I 2 = 0%).
LMWH Versus UFH
Deep vein thrombosis. Four trials including 5,188 patients (13) (14) (15) 23) reported all DVT as an outcome. LMWH was not associated with a lower risk of DVT when compared with UFH (RR, 0.90 [95% CI, 0.74, 1.08]; p = 0.26; I 2 = 0%). Symptomatic DVT was reported in two trials (14, 15) including 4,722 patients; there was no statistically significant difference (RR, 0.87 [95% CI, 0.60, 1.25]; p = 0.44; I 2 = 0%) ( Fig. 2) .
Pulmonary embolism. Two trials including 4,722 patients (14, 15) reported PE. LMWH was associated with a reduction in PE when compared with UFH (RR, 0.62 [95% CI, 0.39, 1.00]; p = 0.05; I 2 = 53%), which translates to a number needed to prophylax to prevent one PE of 132, using an assumed control risk of 2%. Symptomatic PE was reported only in one trial including 3,746 patients (15) ; the use of LMWH was associated with lower risk of symptomatic PE (RR, 0.58 [95% CI, 0.34, 0.97]; p = 0.04). This translates into a number needed to prophylaxis to prevent one symptomatic PE of 119, using an assumed control risk of 2%.
Major bleeding. Three trials including 4,212 patients (13, 15, 23) reported major bleeding. There was no significant difference between LMWH and UFH in major bleeding (RR, 0.97 [95% CI, 0.75, 1.26]; p = 0.83; I 2 = 0%).
Heparin-induced thrombocytopenia. Only one trial enrolling 3,764 patients reported HIT as diagnosed by the serotonin release assay (15) and found no significant difference between the LMWH (0.27%) and UFH (0.64%) groups (RR, 0.42 [95% CI, 0.15, 1.18]; p = 0.10). ICU mortality. Four trials involving 5,184 patients (13-15, 23) reported mortality. There was no difference between groups in the risk of death (RR, 0.93 [95% CI, 0.82, 1.04]; p = 0.20; I 2 = 31%).
Sensitivity Analysis
To explore heterogeneity identified when heparin prophylaxis was compared with placebo for the outcome of DVT (I 2 = 77%; p = 0.004), we conducted an a priori sensitivity analysis excluding articles published only as abstracts. When excluding one abstract (22) from the three trials comparing UFH versus placebo, the remaining two trials showed a more modest treatment ; p = 0.04; I 2 = 32%), suggesting that the large difference in DVT rates between groups reported in this abstract may explain most of the observed heterogeneity. We also excluded one abstract (23) from among the four trials comparing LMWH versus UFH. The remaining three trials showed similar results to the main analysis for DVT (RR, 0.86 [95% CI, 0.70, 1.05]; p = 0.15; I 2 = 0%). When we used odds ratio as a summary statistic, there was no change in the overall results for DVT, although the observed heterogeneity was qualitatively greater (odds ratio, 0.46 [95% CI, 0.24, 1.26]; p = 0.02; I 2 = 82%).
Overall Summary of Findings
We summarize the overall quality of evidence for each outcome in Table 3 .
DISCUSSION
In this systematic review to determine the efficacy and safety of heparin thromboprophylaxis in medical-surgical critically ill patients, seven RCTs enrolling 7,226 patients were included. We found that any heparin compared with no heparin was associated with a 50% lower risk of DVT with a number needed to prophylax of 20. Any heparin also significantly lowered risk of PE by 50% with a number needed to prophylax of 52. Heparin thromboprophylaxis did not influence the risk of major bleeding or mortality. Trials testing UFH used only bid dosing. Although there are no direct comparisons of bid versus tid UFH in any population, indirect comparisons suggest that their effects are similar on thrombosis and bleeding (27) . Compared with UFH, LMWH was associated with a 40% lower risk of PE with a number needed to prophylaxis with LMWH instead of UFH of 132. There were no differences in the risk of DVT, major bleeding, mortality, or HIT in the UFH and LMWH groups. Of the seven trials in this review, only two trials comparing LMWH with UFH reported symptomatic events (14, 15) . One trial that compared LMWH, UFH, and placebo did not show a significant difference in the risk of symptomatic DVT (14) . The use of LMWH was associated with a significant reduction in the risk of PE (number needed to prophylax with LMWH instead of UFH to prevent one PE is 132) and symptomatic PE (number needed to prophylax is 119) (15) . These estimates are derived from trials that did not conduct systematic PE screening; most events were clinically suspected and objectively confirmed, although these trials did not use a standardized diagnostic approach for PE.
Outside of the ICU, clinically important DVTs are sometimes defined as symptomatic events that lead to objective radiologic confirmation and treatment (28, 29) . However, the concept of symptomatic DVT is challenging in critically ill patients, because they cannot reliably communicate symptoms due to impaired consciousness from drugs or their condition. Furthermore, physical signs, such as unilateral leg edema, are uncommon because ICU patients are supine, frequently have bilateral edema, and structured physical examination has been shown to have no diagnostic utility for DVT in medical-surgical critically ill patients (30) .
Accordingly, trials have often used ultrasound screening to detect DVT during critical illness. Surveillance methods used in thromboprophylaxis trials render it unclear what proportion of the largely asymptomatic DVT detected by screening would have become symptomatic if screening had not been used. Although several trials in this review detected DVT by screening (Table 1) , surveillance was not used to diagnose PE. Although there were no standardized diagnostic approaches for PE used in these seven trials, most of the PE events in this review were clinically suspected and a minority was incidental.
If the natural history of VTE in critically ill patients parallels that in other patients, the prevalence of PE in this review is likely to be conservative, because trial patients in whom DVT might develop are typically therapeutically anticoagulated, thereby lowering the risk of thrombus propagation, embolization, and subsequent PE. Thus, a paradox exists, such that asymptomatic DVT rates reported in trials using screening (before symptoms arise) are likely higher than rates of symptomatic DVT that would be identified in practice (when symptoms arise). However, the rates of symptomatic PE reported in trials using screening detection of DVT (given that these DVT are typically treated when identified) are likely lower than the rates of symptomatic PE that would be identified in practice.
There are limitations to the data in this systematic review. Of the seven included trials, two trials reported only one type of VTE outcome (9, 13) , two trials did not report bleeding (9, 22) , two trials did not report mortality (9, 22) and five trials did not report HIT (9, 12, 13, 22, 23) . The primary outcome in most of these trials was lower extremity DVT. In this setting, physicians appear to rely on several population-specific and thrombus-specific factors to assess whether a DVT is clinically important-that is, likely to result in short-term or long-term morbidity or mortality if untreated. In a national survey of ICU physicians, the key patient factors rendering a DVT clinically important were concurrent clinical suspicion of PE, acute or chronic cardiopulmonary morbidity that might limit the tolerance of a PE, and leg symptoms (31) . Of the ultrasound features, venous thrombi that were proximal, large, and totally occlusive characterized a DVT as clinically important (31) . The extent to which these features were present among patients in these trials remains unclear.
Of the LMWHs tested in five of the seven trials in this review, three trials tested enoxaparin (11, 13, 14) , one trial tested dalteparin (15) , and one trial tested nadroparin (12) . In terms of medical-surgical patients exposed to a LMWH in trials, 1,873 patients have received dalteparin, 715 patients have received enoxaparin, and 84 patients have received nadroparin. LMWHs are prepared from UFH by different chemical or enzymatic processes, resulting in differences in their physical, biochemical, and pharmacologic properties (32) . However, whether this translates into differences in clinical outcome is unknown; therefore, whether different LMWH preparations should be considered equivalent and interchangeable in their effect is unclear (33) (34) (35) . LMWH prescribing choices could be based on theoretical or actual differences in pharmacology, known differences in patient outcomes (efficacy and safety), convenience, compliance, cost (acquisition cost which may be modified by bulk purchasing power), cost-effectiveness, availability, applicability, and contracts (which may be influenced by much of the foregoing). In terms of safety among the different LMWHs in medical-surgical patients, observational bleeding risk evaluation research has been conducted using dalteparin (15, 36) . The notion of a class effect existing among LMWHs reflects the comparative randomized trials in noncritically ill patients. An assumption of a class effect underlies the decisions of most thromboprophylaxis clinical practice guidelines which do not specify one of the seven branded LMWHs in their recommendations. However, there are no direct head-to-head comparisons of different LMWHs in randomized trials in the ICU setting, so one cannot definitively conclude either that LMWHs exhibit a class effect or not (37) . We consequently report details of each LMWH trial and pool data in this systematic review. Clearly, in the absence of comparative data, each LMWH should be used at the recommended doses when efficacy and safety data exist.
Following the American College of Chest Physicians' Antithrombotic Therapy and Prevention of Thrombosis Guidelines (38) , the quality of evidence related to the outcome of any DVT is downgraded on the basis of indirectness due to screening methods used. Risk of bias is also conferred by heterogeneity for a few outcomes ( Table 2) . Although the total number of events and patients represented in several comparisons exceeds the threshold of the optimal information size (39), we conservatively downgraded the quality of evidence for some endpoints with very few events due to imprecision. The small number of trials available precluded subgroup analyses to explore heterogeneity of pooled results based on risk of bias, and the two trials published only in abstract form had limited reporting, leading to an unclear risk of bias in most domains. Data were not available in a manner that allowed analysis of subgroup differences between medical and surgical patients. Data are sparse on upper extremity DVTs. Mechanical prophylaxis was used routinely in some trials included in this review and in some trials only if heparin was contraindicated (Table 1) . However, the effect of antiembolic stockings has been called into question by the Clots in Legs Or sTockings after Stroke (CLOTS)-1 (40) and CLOTS-2 (41) trials, and pneumatic compression devices have not been tested in trials in this population. Given the foregoing uncertainty about their effectiveness, their low utilization in these trials overall, and the similar distribution across arms in these trials if they were used, we do not believe that the presence or absence of mechanical prophylaxis materially influences the results of this systematic review. Nevertheless, the results of this systematic review summarize the only RCT evidence about the consequences of heparin thromboprophylaxis in a range of general medical and surgical ICU conditions. Strengths of this systematic review include the comprehensive search strategy using three databases and a trials registry, explicit inclusion and exclusion criteria resulting in high agreement on relevant trials, and incorporation of abstracts to minimize risk of publication bias. We compared any type of heparin thromboprophylaxis versus no heparin and directly compared UFH versus LMWH. Trial selection, data abstraction, and quality assessment were conducted in duplicate. We used the Cochrane risk of bias approach, abstracted all potentially relevant outcomes, contacted trial authors, and adapted GRADE criteria to guide interpretation of results. These results complement estimates from trials in general medical patients (1, 2) and surgical populations (3, 42) yielding similar findings. While always considering patient characteristics and preferences, drug availability, and changing drug costs, these findings could help inform practice and aid future guideline developers.
CONCLUSIONS
Considering the nearly universal use of anticoagulant thromboprophylaxis in medical-surgical ICU patients and its incorporation into hospital accreditation and quality of care metrics, population-specific trial data for medical-surgical critically ill patients are relatively sparse. However, trial evidence to date suggests that any type of heparin thromboprophylaxis decreases DVT and PE in medical-surgical critically ill patients, and LMWH compared with bid UFH decreases PE and symptomatic PE. Major bleeding and mortality rates do not appear to be significantly influenced by heparin thromboprophylaxis in the ICU setting. Trial methodology, indirectness, and the heterogeneity and imprecision of some results temper inferences from this literature.
